Suppr超能文献

将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。

Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.

机构信息

BioMedCom Consultants, Inc., Dorval, Quebec, Canada (MMG, MW, HK, RJL, LJE, DR)

Centre Hospitalier Universitaire de Montre´ al—McGill University Hospital Center (CHUM-MUHC) Technology Assessment Unit, Montreal, Quebec, Canada (LJE).

出版信息

Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.

Abstract

BACKGROUND

Health care decision making is complex and requires efficient and explicit processes to ensure transparency and consistency of factors considered.

OBJECTIVES

To pilot an adaptable decision-making framework incorporating multicriteria decision analysis (MCDA) in health technology assessment (HTA) with a pan-Canadian group of policy and clinical decision makers and researchers appraising 10 medicines covering 6 therapeutic areas.

METHODS

An appraisal group was convened and participants were asked to express their individual perspectives, independently of the medicines, by assigning weights to each criterion of the MCDA core model: disease severity, size of population, current practice and unmet needs, intervention outcomes (efficacy, safety, patient reported), type of health benefit, economics, and quality of evidence. Participants then assigned performance scores for each medicine using available evidence synthesized in a "by-criterion" HTA report covering each of the MCDA CORE model criteria. MCDA estimates of perceived value were calculated by combining normalized weights and scores. Feedback on the approach was collected through structured discussion.

RESULTS

Relative weights on criteria varied widely, reflecting the diverse perspectives of participants. Scores for each criterion provided a performance measure, highlighting strengths and weaknesses of each medicine. MCDA estimates of perceived value ranged from 0.42 to 0.64 across medicines, providing comprehensive measures incorporating a large spectrum of criteria. Participants reported that the framework provided an efficient approach to systematic consideration in a pragmatic format of the multiple elements guiding decision, including criteria and values (MCDA core model) and evidence (HTA "by-criterion" report).

CONCLUSIONS

This proof-of-concept study demonstrated the usefulness of incorporating MCDA in HTA to support transparent and systematic appraisal of health care interventions. Further research is needed to advance MCDA-based approaches to more effective healthcare decision making.

摘要

背景

医疗保健决策复杂,需要高效、明确的流程,以确保考虑因素的透明度和一致性。

目的

在涵盖 6 个治疗领域的 10 种药物的评估中,与加拿大各地的政策和临床决策者以及研究人员一起,试用一种可适应的决策框架,将多准则决策分析(MCDA)纳入健康技术评估(HTA)中。

方法

召集了一个评估小组,要求参与者通过为 MCDA 核心模型的每个标准分配权重,独立于药物来表达他们的个人观点:疾病严重程度、人口规模、当前实践和未满足的需求、干预结果(疗效、安全性、患者报告)、健康效益类型、经济学和证据质量。然后,参与者使用涵盖 MCDA CORE 模型每个标准的“按标准”HTA 报告中综合的可用证据,为每种药物分配绩效得分。通过组合归一化权重和分数,计算出 MCDA 感知价值的估计值。通过结构化讨论收集了对该方法的反馈。

结果

标准的相对权重差异很大,反映了参与者的不同观点。每个标准的得分提供了一种绩效衡量标准,突出了每种药物的优势和劣势。MCDA 感知价值的估计值在药物之间的范围从 0.42 到 0.64,提供了全面的衡量标准,包含了广泛的标准。参与者报告称,该框架提供了一种高效的方法,以务实的格式系统地考虑指导决策的多个要素,包括标准和价值观(MCDA 核心模型)和证据(HTA“按标准”报告)。

结论

这项概念验证研究表明,将 MCDA 纳入 HTA 以支持医疗保健干预措施的透明和系统评估是有用的。需要进一步研究推进基于 MCDA 的方法,以实现更有效的医疗保健决策。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验